20-F: InMode Expands Lease Agreements and Navigates Market Volatility in 2024

InMode Ltd. expands its operational footprint with new lease agreements while facing revenue decline and legal challenges in 2024.

Summary

• InMode Ltd., a global provider of energy-based medical devices, has filed its 20-F report detailing its activities and financial performance.
• The company expanded its lease agreements for its headquarters in Yokneam, Israel, with the sixth and seventh supplemental agreements signed in June and July 2024, respectively.
• InMode's revenue decreased by 20% to $394.8 million in 2024, compared to $492.0 million in 2023, due to a decrease in sales of minimally invasive platforms worldwide.
• Net income also decreased to $181.3 million in 2024 from $197.9 million in 2023.
• The company is facing a securities class action lawsuit filed in February 2024, alleging false or misleading statements related to its business and financial outlook.
• InMode has implemented a share repurchase program, purchasing 16.05 million ordinary shares for $285.4 million in 2024.
• The company's operating costs could be adversely affected by climate-related events and increasing regulatory requirements and security.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While InMode is expanding its operational footprint, it is also facing revenue decline, a securities class action lawsuit, and potential risks related to its operations in Israel and the global economy.

Positives

• InMode continues to innovate with new product platforms like IgniteRF and OptimasMAX.
• The company maintains a strong gross margin of approximately 80% in 2024.
• InMode has a significant cash reserve of $596.5 million in cash and cash equivalents, marketable securities and short-term bank deposits.
• The company has a strong management team with a proven track record.

Negatives

• Revenue decreased by 20% to $394.8 million in 2024, compared to $492.0 million in 2023.
• Net income decreased to $181.3 million in 2024 from $197.9 million in 2023.
• The company is facing a securities class action lawsuit alleging false or misleading statements.

Risks

• The company's success depends on market acceptance of its products.
• Product liability suits could be brought against InMode due to defective material or design or misuse of its products.
• The impact of the political, economic and military instability in Israel and the ongoing Israel-Hamas war could impede InMode's ability to operate.
• If InMode is unable to protect its intellectual property rights, its competitive position could be harmed.
• The company's operating costs and business operations could be adversely affected by climate-related events and increasing regulatory requirements and security.

Future Outlook

InMode plans to increase its sales presence, penetrate its existing customer base further, leverage its existing technology to expand into new applications, and actively pursue business development opportunities.

Industry Context

The medical aesthetics market is highly competitive and dynamic, marked by rapid technological development and product innovations.

Comparison to Industry Standards

• InMode competes with public companies like AbbVie Inc., Cutera, Inc., Apyx Medical Corporation, Venus Concept Inc. and Sisram Medical Ltd, as well as private companies, such as Cynosure LLC, Lumenis Ltd., BTL Aesthetics, Inc. and Candela Medical Inc.
• Competition with these companies could result in reduced prices and profit margins and loss of market share.
• InMode also faces competition from medical aesthetic products, including Botox, hyaluronic acid injections and collagen injections, and aesthetic procedures, such as face lifts, liposuction, sclerotherapy, electrolysis, chemical peels and laser procedures.

Legal Proceedings

• A securities class action lawsuit was filed against InMode and certain of its officers and directors in February 2024, alleging false or misleading statements related to the company's business and financial outlook.

Related Party Transactions

• InMode receives and provides certain services from and to Home Skinovations Ltd., a related party.
• InMode receives certain investment portfolio management services from Himalaya Family Office Consulting Ltd., where the CEO is a minor shareholder and board member.

Stakeholder Impact

• Shareholders may be impacted by the decrease in revenue and net income, as well as the ongoing securities class action lawsuit.
• Employees may be impacted by potential changes in operations due to the ongoing Israel-Hamas war and other conflicts in the region.
• Customers may be impacted by potential disruptions in the supply chain due to the ongoing Israel-Hamas war and other conflicts in the region.

Next Steps

• InMode intends to expand its sales presence globally.
• The company plans to leverage its existing technology to expand into new minimally and non-invasive applications.
• InMode will actively pursue business development opportunities, including potential acquisitions and strategic partnerships.

Key Dates

Keywords

InMode, lease agreement, financial results, medical devices, share repurchase, litigation, risk factors, revenue, aesthetics